madman
Super Moderator
Marius got this s**t on lock!
* This newly allowed patent provides additional protection for KYZATREX through 2040 and further underscores the unique formulation and delivery attributes that differentiate it from other testosterone replacement therapies.
* With six patents now protecting our therapy and more in progress, we are confident in our ability to remain insulated from generic disruption and compounding threats as KYZATREX becomes the go-to therapy option in this 25 million plus patient market.”
www.globenewswire.com
RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the United States Patent and Trademark Office (USPTO) for a new patent related to its oral testosterone therapy, KYZATREX® (testosterone undecanoate) CIII Capsules. This is the sixth patent in the company’s growing intellectual property portfolio protecting KYZATREX.
This newly allowed patent provides additional protection for KYZATREX through 2040 and further underscores the unique formulation and delivery attributes that differentiate it from other testosterone replacement therapies. It reinforces the significant barriers to generic or compounded alternatives, and strengthens Marius Pharmaceuticals’ confidence in the durability of its proprietary, business model.
“This patent reinforces our commitment to evidence-based, precision treatment of testosterone deficiency,” said Shalin Shah, CEO at Marius Pharmaceuticals. “By securing additional protection for KYZATREX, we continue to lead the way in oral testosterone innovation, making it easier for providers to deliver safe, effective care tailored to individual patient needs. With six patents now protecting our therapy and more in progress, we are confident in our ability to remain insulated from generic disruption and compounding threats as KYZATREX becomes the go-to therapy option in this 25 million plus patient market.”
The USPTO issues a Notice of Allowance when it determines that a patent application has met all formal requirements. This patent will extend protection for KYZATREX in the U.S. through 2040.
It adds to Marius’ robust global patent estate, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand, and other key markets, with pending applications in India and the U.S.
* This newly allowed patent provides additional protection for KYZATREX through 2040 and further underscores the unique formulation and delivery attributes that differentiate it from other testosterone replacement therapies.
* With six patents now protecting our therapy and more in progress, we are confident in our ability to remain insulated from generic disruption and compounding threats as KYZATREX becomes the go-to therapy option in this 25 million plus patient market.”
Marius Pharmaceuticals Receives Sixth U.S. Patent Allowance for KYZATREX® (testosterone undecanoate) CIII Capsules Extending Coverage to 2040
RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for...
RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the United States Patent and Trademark Office (USPTO) for a new patent related to its oral testosterone therapy, KYZATREX® (testosterone undecanoate) CIII Capsules. This is the sixth patent in the company’s growing intellectual property portfolio protecting KYZATREX.
This newly allowed patent provides additional protection for KYZATREX through 2040 and further underscores the unique formulation and delivery attributes that differentiate it from other testosterone replacement therapies. It reinforces the significant barriers to generic or compounded alternatives, and strengthens Marius Pharmaceuticals’ confidence in the durability of its proprietary, business model.
“This patent reinforces our commitment to evidence-based, precision treatment of testosterone deficiency,” said Shalin Shah, CEO at Marius Pharmaceuticals. “By securing additional protection for KYZATREX, we continue to lead the way in oral testosterone innovation, making it easier for providers to deliver safe, effective care tailored to individual patient needs. With six patents now protecting our therapy and more in progress, we are confident in our ability to remain insulated from generic disruption and compounding threats as KYZATREX becomes the go-to therapy option in this 25 million plus patient market.”
The USPTO issues a Notice of Allowance when it determines that a patent application has met all formal requirements. This patent will extend protection for KYZATREX in the U.S. through 2040.
It adds to Marius’ robust global patent estate, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand, and other key markets, with pending applications in India and the U.S.
